Most Read Articles
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Jairia Dela Cruz, 06 Sep 2019
Low-dose dexamethasone and prednisolone are equally effective in the treatment of croup in children, according to data from the Topdog* trial.
11 Sep 2019
Early brain injury and at least one sensorimotor immaturity precede cerebral palsy (CP) in very preterm infants and may be considered as reliable predictors, a recent study has found.
Jairia Dela Cruz, 04 Sep 2019
Parenteral antibiotic therapy duration for bacteraemic urinary tract infection (UTI) in young infants may be safely shortened, according to a recent study showing that recurrence and readmission or emergency department revisitation rates are comparable between a ≤7-day and a longer therapy course.

Add-on mirabegron safe for treating paediatric overactive bladder

23 Dec 2016

Therapy regimens with add-on mirabegron may be safely used in children with refractory overactive bladder, according to data from a prospective off-label study.

A total of 35 overactive bladder paediatric patients (median age 10.3 years) received treatment with add-on mirabegron. All patients did not present symptom improvement under intensive behavioural and medical therapies and/or had significant side effects on antimuscarinic dose escalation.

The primary endpoint was better-reported efficacy compared with the use of prior antimuscarinic monotherapy. Secondary endpoints were tolerability, safety and satisfaction.

Efficacy and tolerability were evaluated using voiding diaries, post-void residuals (PVR), urine cultures, ECG and vital signs. Families were interviewed for continence, side effects and compliance. Statistical analysis was performed using Wilcoxon signed rank test.

Following treatment with add-on mirabegron for a median of 16.4 months, median bladder capacity improved from 50 percent to 74 percent expected bladder capacity (p<0.001).

Furthermore, continence improved in all patients, and 12 patients were reported to be completely dry.

On the other hand, two patients had an increase in post-void residual, and one developed urinary tract infection. Side effects, which were mild to moderate in severity, were reported in seven patients.

There were two cases of treatment discontinuation, one due to side effects and another to post-void residual.

These data highlight the potential of add-on mirabegron in the treatment of refractory overactive bladder, with the drug being safe and well-tolerated in children.

Mirabegron, a β3-adrenoreceptor agonist, has been shown to improve the storage capacity of the bladder, without impairing bladder contraction during voiding. The agent is rapidly absorbed after oral administration and is metabolized in the liver via multiple pathways. Caution must be exercised when using mirabegron in patients receiving ketoconozole or other potent CYP3A inhibitors as mirabegron may be subject to clinically relevant drug–drug interactions. [Neurourol Urodyn 2014;33:17–30]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Jairia Dela Cruz, 06 Sep 2019
Low-dose dexamethasone and prednisolone are equally effective in the treatment of croup in children, according to data from the Topdog* trial.
11 Sep 2019
Early brain injury and at least one sensorimotor immaturity precede cerebral palsy (CP) in very preterm infants and may be considered as reliable predictors, a recent study has found.
Jairia Dela Cruz, 04 Sep 2019
Parenteral antibiotic therapy duration for bacteraemic urinary tract infection (UTI) in young infants may be safely shortened, according to a recent study showing that recurrence and readmission or emergency department revisitation rates are comparable between a ≤7-day and a longer therapy course.